Navigation Links
World Glaucoma Day Set For March 12, 2009
Date:2/12/2009

The New York Eye and Ear Infirmary Joins International Observance To Draw Attention To "The Sneak Thief of Sight"

NEW YORK, Feb. 12 /PRNewswire-USNewswire/ -- In an effort to combat one of the leading causes of blindness worldwide, the World Glaucoma Association and the World Glaucoma Patient Organization have set March 12, 2009, as the second annual World Glaucoma Day. The day will be marked by awareness and educational events organized by eye care institutions and local patient support groups on every continent, as listed on www.wgday.net.

Glaucoma is the second leading cause of blindness in the United States and the leading cause in African-Americans. About 50% of persons with glaucoma in the United States are unaware that they have it, while this number can reach 90% in developing countries.

Known as "the sneak thief of sight," glaucoma is characterized by gradual loss of vision resulting from death of the cells in the eye which transmit visual images through the optic nerve to the brain. As the optic nerve becomes increasingly damaged, permanent vision loss occurs and can result in blindness. Early detection is the key to treating and halting the effects of glaucoma.

"Because glaucoma strikes so silently and gradually, it is absolutely crucial to educate people about the value of early detection," said Robert Ritch, MD, professor and chief of glaucoma services at The New York Eye and Ear Infirmary, co-founder of the World Glaucoma Patient Association, and member of the World Glaucoma Day committee for the World Glaucoma Association. "For a disease that causes permanent blindness, it is truly unacceptable that so many people remain unaware of its impact and consequences."

To emphasize the universal importance of early detection, Dr. Ritch and colleagues plan a glaucoma screening for dele
'/>"/>

SOURCE The New York Eye & Ear Infirmary
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medical Tourism Comes to Macao -- Worlds Largest Integrative One-Stop Wellness Centre MaloClinicSPA Opens at The Venetian(R) Macao-Resort-Hotel
2. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
3. Sensiotec Announces FDA 510(k) Class II Clearance for the Worlds First UWB Healthcare Unbound, Wireless, Non-Contact, Vital Signs and Movement Monitor
4. Worlds First Cardiac Adult Stem Cell Trial to Take Place in Louisville
5. HTH Worldwide to Provide Mobile Healthcare Tool to UNIGLOBE Travel Internationals Agencies
6. Healthcare Online Regulations to Be Discussed in Live Event and Webcast Hosted by Waggener Edstrom Worldwide
7. Healthcare Online Regulations Discussed in Live Event and Webcast Hosted by Waggener Edstrom Worldwide
8. WorldHeart Appoints New President and CEO
9. World Cancer Day Highlights Link Between Overweight and Cancer
10. "Viral Campaign May Lead to Guinness World Record"
11. How much is the world spending on neglected disease research and development?
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New Executive Leadership and CEO Announced for BiPar Sciences 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Caldolor 28R 29 28Ibuprofen 29 Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 6465 1Caldolor 28R 29 28Ibuprofen 29 Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 6465 2Caldolor 28R 29 28Ibuprofen 29 Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 6465 3Sarnova Expands Senior Management Team 6463 1Sarnova Expands Senior Management Team 6463 2Proteon Initiates Second Phase 1 2 Clinical Study of PRT 201 in Hemodialysis Patients 6461 1Proteon Initiates Second Phase 1 2 Clinical Study of PRT 201 in Hemodialysis Patients 6461 2